A multi-year initiative by the American Heart Association, with the support of Amgen, equips participants with tools to create a lasting culture of health DALLAS, September 27, 2022 — The American Heart Association, the world’s leading nonprofit...
MarketsandResearch.biz really dispersed a general report named Global Colorectal Cancer Drugs Market
In a report currently being published by Verified Market Research titled “Global Tumor Necrosis
Chronic Lymphocytic Leukemia Market study by “marketreports.info” provides details about
Nonrandomized trial shows 5%-6% reduction in both visceral and subcutaneous fat, but no effect on aortic vascular inflammation.
This week in Other Barks & Bites: the U.S. Solicitor General files a brief with the Supreme Court recommending denial of a petition for writ of certiorari in Amgen case; Stephen Thaler files a petition for rehearing at the Federal Circuit in his ongoing attempts to have DABUS AI recognized as an inv…
An Ionis Pharmaceuticals heart disease drug beat a placebo in a mid-stage clinical trial, but partner AstraZeneca has decided it won’t advance the genetic medicine to a larger Phase 3 test. The results were apparently not enough to set the Ionis therapy apart from commercialized cholesterol-lowering…
The Biden Administration told the U.S. Supreme Court on Wednesday that it should turn down a request by Amgen Inc to review a decision that invalidated patents on its blockbuster cholesterol drug Repatha.
Shares of Amgen Inc. slid 1.43% to $224.46 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...
Investigators at Washington State University (WSU) have identified a set of eight proteins that were expressed in the serum of Ursus arctos horribilis, better known as the grizzly bear, specifically during their hibernation period. In addition to reporting new basic insights into hibernation, the st…
by Dennis Crouch The Solicitor General’s new brief in Amgen v. Sanofi shrugs off the case--identifying petitioner’s arguments as meritless: …
Lessons from Hurricane Maria prepared pharmaceutical and device manufacturers like Baxter and Boston Scientific to manage the current disaster.
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.43% on an annualized basis producing an average annual return of 9.79%. Currently, Amgen has a market capitalization of $122.73 billion.
In NASH, positive readouts don’t come too often. Yet according to Akero, today is that day. Akero reported results from its 24-week HARMONY Phase IIb trial bright and early Tuesday, looking at lead candidate and ex-Amgen drug efruxifermin, or EFX, in 128 patients with biopsy-confirmed, pre-cirrhotic…
Robert W. Baird reissued an “underperform” rating and set a $185.00 price objective on shares of Amgen in a research note on Tuesday.
Large observational databases mitigate concerns about the osteoporosis therapy
Wall Street advanced to two-week highs on Monday with few impediments to thwart a three-day winning streak as investors awaited crucial inflation data. All three major U.S. stock indexes... | September 13, 2022
” Glioblastoma multiforme (GBM) is the most common malignant (high-grade) brain tumor. It develops from star-shaped glial cells, which are the cells that surround and support nerve cells. It is also called a stellate or glial cell tumor and usually originates in the cerebral hemisphere. Most GBM tum…
Bristol Myers Squibb made a megablockbuster bet on deucravacitinib, an in-house experimental TYK2 drug, in the leadup to the big Celgene buyout, keeping it while auctioning off Celgene’s top-selling Otezla to Amgen for $13.4 billion. Friday evening, that bet paid off in a landmark win, with Bristol…
The biotech industry is poised to grow thanks to breakthrough developments and increasing demand from an aging population. Fundamental strength and inelastic demand have been helping biotech stocks Amgen Inc. (AMGN) and Gilead Sciences, Inc. (GILD) defy the bear market. However, Timber Pharmaceutica…